Nutriband Stock
Nutriband Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Gareth Sheridan
- Employees
- 13
- Market cap
- $76 M
- IPO
- 01/10/2021
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and…
Nutriband stock: price history
1D
-0.8%
1W
-6.5%
1M
-11.6%
6M
+44.7%
YTD
+37.0%
1Y
-19.2%
2Y
-17.3%
5Y
-8.7%
10Y
–
Next earnings date
Next earnings date
07/12/2026 (in 51 days)
Volatility around earnings
~10% weaker price swings than usual
Ask the agents about Nutriband
Analyst assessment of Nutriband
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 26/07/2022
Nutriband stock metrics
P/E
-10.87
P/B
14.19
EV/EBITDA
-10.63
RETURN ON EQUITY
-16.5%
NET MARGIN
-201.3%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
31/07/2026
Free float & liquidity
FREE FLOAT
43.4%
FLOAT SHARES
5,279,699
AVG. DAILY VOLUME (30D)
111,532
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Nutriband stock
What does Nutriband do?
Nutriband Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Gareth Sheridan, the company employs around 13 people.
The IPO was on 01/10/2021; the stock trades on NASDAQ under the ticker NTRB.
What do analysts say about Nutriband stock?
1 analysts rate the stock, the consensus is Buy (as of 26/07/2022).
This is an external assessment, not a statement by Market Jury.
When does Nutriband report next?
The next earnings date is 07/12/2026.
Around past earnings, price swings were roughly -10% stronger than usual.
Does Nutriband pay a dividend?
No, Nutriband currently does not pay a dividend.
Which stocks are comparable to Nutriband?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Nutriband stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nutriband against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.